Zobrazeno 1 - 10
of 730
pro vyhledávání: '"Tianshu LIU"'
Autor:
Jing Wu, Shilong Zhang, Shan Yu, Guo An, Yi Wang, Yiyi Yu, Li Liang, Yan Wang, Xiaojing Xu, YanShi Xiong, Di Shao, Zhun Shi, Nannan Li, Jingyuan Wang, Dawei Jin, Tianshu Liu, Yuehong Cui
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-15 (2024)
Abstract Vascular endothelial growth factor inhibitors, including tyrosine kinase inhibitors (TKIs), possess immunomodulatory properties and have shown promising outcomes when combined with anti-PD-1 antibodies. The OASIS phase II trial (NCT04503967)
Externí odkaz:
https://doaj.org/article/02bedb12c5e649a694ae55e114afd924
Autor:
Pan Ran, Aoqian Qiu, Tianshu Liu, Fangyuan Wang, Bailin Tian, Beiyao Xiang, Jun Li, Yang Lv, Mengning Ding
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract Production of epoxides via selective oxidation of olefins affords a fundamental source of key intermediates for the industrial manufacture of diverse chemical stocks and materials. Current oxidation strategy generally works under harsh condi
Externí odkaz:
https://doaj.org/article/64b7468911864b7d8f1c873ee89fe451
Autor:
Jingyuan Wang, Joanne Xiu, Francesca Battaglin, Hiroyuki Arai, Shivani Soni, Wu Zhang, Richard M. Goldberg, Philip A. Philip, Andreas Seeber, Jimmy J. Hwang, Anthony F. Shields, John L. Marshall, Igor Astaturov, Tianshu Liu, A. Craig Lockhart, W. Michael Korn, Lin Shen, Heinz-Josef Lenz
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-10 (2024)
Abstract Although histological and molecular classifications have been extensively studied for gastric cancer (GC), targeted therapies for GC remain limited. CDH1 mutations (MT) are characteristic of genomically stable GC and are associated with poor
Externí odkaz:
https://doaj.org/article/a3d469c1d6cf430091e90de7ea2adb8c
Autor:
Jian Zhang, Yiqun Du, Yanchun Meng, Xiaojun Liu, Yuxin Mu, Yunpeng Liu, Yehui Shi, Jufeng Wang, Aimin Zang, Shanzhi Gu, Tianshu Liu, Huan Zhou, Hongqian Guo, Silong Xiang, Xialu Zhang, Suqiong Wu, Huanhuan Qi, Mengke Li, Xichun Hu
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-9 (2024)
Abstract DP303c is a HER2-targeted ADC with a cleavable linker-MMAE payload. Previous in vitro studies demonstrated that DP303c showed similar or better antitumor activity than T-DM1 in xenograft models. This was a multicenter, dose escalation and do
Externí odkaz:
https://doaj.org/article/e373209687f84f2f8062a4819767885a
Autor:
Qing Liu, Mengling Liu, Zhiguo Zou, Jinyi Lin, Ningping Zhang, Lin Zhao, Jiahua Zhou, Haojie Zhou, Xin Zhou, Xiaodong Jiao, Yiyi Yu, Tianshu Liu
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-11 (2024)
Abstract Background Treatment strategy against immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) frequently requires other immunosuppressive agents. Tofacitinib is a rapidly acting JAK-STAT inhibitor with proven eff
Externí odkaz:
https://doaj.org/article/0e8938951843488299fc84183f272dff
Autor:
Xiaojing Xu, Luoyan Ai, Keshu Hu, Li Liang, Minzhi Lv, Yan Wang, Yuehong Cui, Wei Li, Qian Li, Shan Yu, Yi Feng, Qing Liu, Ying Yang, Jiao Zhang, Fei Xu, Yiyi Yu, Tianshu Liu
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Immunotherapy confers little to no benefit in the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Mechanistic insights suggested that epidermal growth factor receptor (EGFR) antibody plus irinotecan might augmen
Externí odkaz:
https://doaj.org/article/c52ef4cf4de347268916103efecfb9a4
Autor:
Jiayu Zhang, Yu Dong, Shan Yu, Keshu Hu, Lingyun Zhang, Min Xiong, Mengling Liu, Xun Sun, Suyao Li, Yitao Yuan, Chi Zhang, Mengxuan Zhu, Yichou Wei, Yanjing Zhu, Yiyi Yu, Pengfei Zhang, Tianshu Liu
Publikováno v:
Cell Death and Disease, Vol 15, Iss 7, Pp 1-15 (2024)
Abstract In recent years, immunotherapy, particularly PD-1 antibodies, have significantly enhanced the outcome of gastric cancer patients. Despite these advances, some patients do not respond well to treatment, highlighting the need to understand res
Externí odkaz:
https://doaj.org/article/e36a9c12b7294c108f7913e3bfca937c
Autor:
Yuankai Shi, Xiaohong Han, Qian Zhao, YuLong Zheng, Jianhua Chen, Xinmin Yu, Jian Fang, Yutao Liu, Dingzhi Huang, Tianshu Liu, Hong Shen, Suxia Luo, Hongsheng Yu, Yu Cao, Xi Zhang, Pei Hu
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-12 (2024)
Abstract Background Tunlametinib (HL-085) is a novel, highly selective MEK inhibitor with substantial clinical activities in patients with NRAS-mutant melanoma. This phase I study evaluated the safety and preliminary efficacy of tunlametinib plus vem
Externí odkaz:
https://doaj.org/article/0f192aa657bc4c0d996fc74a75cf28e7
Autor:
Zheng Li, Rui Zhao, Cong Wang, Yan Wang, Jinyi Lin, Shihai Zhao, Jiahui Chen, Yuhong Zhou, Tianshu Liu, Feng Wang, Xianhong Shu, Mengsu Zeng, Leilei Cheng
Publikováno v:
ESC Heart Failure, Vol 11, Iss 2, Pp 1061-1075 (2024)
Abstract Aims To assess the different imaging characteristics between corticosteroid‐sensitive (CS) and corticosteroid‐refractory (CR) immune checkpoint inhibitor‐associated myocarditis (ICIaM) with cardiac magnetic resonance (CMR) and the pote
Externí odkaz:
https://doaj.org/article/d81826a4337e482da9eaf8de41157fab
Autor:
Yiyi Yu, Zhening Zhang, Mengxuan Zhu, Yu Shan, Yan Wang, Li Wei, Xuan Huang, Debin Sun, Zhao Peng, Tianshu Liu
Publikováno v:
Clinical and Translational Discovery, Vol 4, Iss 4, Pp n/a-n/a (2024)
Abstract Background Despite advances in treatments for gastric cancer (GC), new targets are needed to enhance treatment, especially when mesenchymal‐epithelial transition (MET) amplification is involved. Therefore, we investigated the genomic featu
Externí odkaz:
https://doaj.org/article/4d4e0183926441c6b7abf10b8865a1e1